The invention provides a method of noninvasively treating a condition associated with reduced integrity or increased permeability of an epithelial layer by a series of magnetic pulses having a magnitude of up to 3 T, wherein the magnetic pulses are designed to induce an electric field having a magnitude of up to 250 Volt per meter adjacent to a target treatment area, the condition particularly being ocular condition associated with reduced barrier function of the cornea. The invention provides a device for effecting the tissue treatment, creating series of pulses exhibiting a rate of change of more than 200 T/s in the absolute value.

Disclosed is a therapeutic lamp platform controller. According to an exemplary embodiment of this disclosure, provided is a controller comprising a power source; a control circuit operatively connected to the power source, the control circuit including one or more outputs to drive a plurality of radiant lamps associated with a therapeutic lamp platform, the plurality of radiant lamps including a mixed combination of different wavelength radiant energy and the plurality of radiant lamps disposed to communicate the radiant energy to a user treatment area; a user display operatively connected to the control circuit; and a user control switch operatively connected to the control circuit, wherein the control circuit is configured to control a dosage amount of radiant energy communicated to the user treatment area.

A method of preventing capsular opacification and fibrosis after cataract extraction and and/or preventing fibrosis around a shunt or stent after glaucoma surgery is disclosed herein. In the cataract procedure, after the cortex and nucleus of the natural lens with the cataract has been removed, a photosensitizer is applied inside the lens capsule, a posterior portion of the lens capsule is irradiated so as to activate cross-linkers and prevent capsular opacification and fibrosis, and an intraocular lens is inserted into the lens capsule. In the glaucoma procedure, a fluid drainage opening is formed and/or a stent is inserted into the eye, a photosensitizer is applied inside an anterior chamber of the eye so that a diffused stream of the photosensitizer travels through the fluid drainage opening or the stent, and the tissue surrounding the fluid drainage opening or the stent is irradiated so as to activate cross-linkers and prevent fibrosis.

The present invention relates to an ophthalmic treatment apparatus and to a beam control method therefor. The ophthalmic treatment apparatus according to the present invention comprises: a beam generating unit for generating beams having different pulse energies; a bubble sensing unit for sensing whether or not bubbles have been generated, as well as the amount of generated bubbles, on the basis of the pulse energy of the beam generated by the beam generating unit and radiated onto the treatment region of an eyeball; and a control unit for controlling the operation of the beam generating unit such that the pulse energy of the beam generated by the beam generating unit can be adjusted in accordance with the signal from the bubble sensing unit.

A high-divergence-angle optical fiber apparatus is disclosed that includes a multimode optical fiber having a distal end and a divergence angle . A light-redirecting structure is operably disposed at the distal end and consists of an array of between 1 and 10 layers of fused glass microspheres. The light-redirecting structure defines a divergence angle , wherein 2. A light source system that utilizes the high-divergence-angle optical fiber apparatus is also disclosed.

Compositions and methods for repairing or regenerating damaged tissue are disclosed. In particular, the invention relates to methods of anchoring biomolecules and/or cells to tissues in order to immobilize and concentrate therapeutic factors that promote tissue regeneration at or under the surface of damaged tissue.

An apparatus for the treatment and/or prevention of corneal diseases includes an applicator head. The applicator head includes a radiation source capable of exciting a non-toxic chromophore. A control is operable to activate the radiation source to radiate, wherein at least one of the following two conditions is met: the applicator head includes a sensor capable of measuring a signal dependent on a position of the applicator head relative to the cornea; or, the applicator head is configured to be in physical contact with the cornea. The control is operable to activate the radiation source to radiate depending on a signal measured by the sensor or to activate the radiation source when the applicator head touches the cornea, respectively.

Ophthalmic treatment systems and methods of using the systems are disclosed. The ophthalmic treatment systems include (a) a light source device; (b) at least one optical treatment head operatively coupled to the light source device, comprising a light source array, and providing at least one treatment light; and (c) a light control device, which (i) provides patterned or discontinuous treatment light projection onto an eye (e.g., the cornea and/or sclera of an eye); or (ii) adjusts intensity of part or all of the light source array, providing adjusted intensity treatment light projection onto an eye (e.g., the cornea and/or sclera of an eye). The at least one treatment light promotes corneal and/or scleral collagen cross-linking.

Ophthalmic treatment systems and methods of using the systems are disclosed. The ophthalmic treatment systems include (a) a light source device; (b) at least one optical treatment head operatively coupled to the light source device, comprising a light source array, and providing at least one treatment light; and (c) a light control device, which (i) provides patterned or discontinuous treatment light projection onto an eye (e.g., the cornea and/or sclera of an eye); or (ii) adjusts intensity of part or all of the light source array, providing adjusted intensity treatment light projection onto an eye (e.g., the cornea and/or sclera of an eye). The at least one treatment light promotes corneal and/or scleral collagen cross-linking.

A light-guided, ophthalmic-treatment-system for administering therapeutic agents to, into or through the scleral wall of the eye globe using any one of a variety of therapeutic applicators in conjunction with either transcorneal or transpupillary viewing methods or both.